A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2018
Price : $35 *
At a glance
- Drugs BCT 100 (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Bio-Cancer Treatment International
- 31 Aug 2018 Biomarkers information updated
- 25 Jan 2018 Last checked against ClinicalTrials.gov record.
- 27 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.